May 2013, Vol 4, No 4

Early palliative care proved to be cost-effective and cost-saving versus routine end-of-life care for patients with recurrent platinum-resistant ovarian cancer, according to a decision-model analysis.
Read Article

Hollywood, FL—Community oncology will not survive in the absence of novel management strategies and process improvements, according to Michael Kolodziej, MD, FACP, National Medical Director of Oncology Solutions, who offered his insights at the Third Annual Conference of the Association for Value-Based Cancer Care.
Read Article

One of the FDA’s highest priorities at the moment is providing guidance on drugs and medical devices to drug and device companies on their use of social media, according to Tom Abrams, head of the FDA’s Office of Prescription Drug Promotion.
Read Article

The FDA warned healthcare professionals about potential medication errors resulting from confusion with the nonproprietary name for the recently approved breast cancer drug ado-trastuzumab emtansine (Kadcyla; also known as T-DM1).
Read Article





Hollywood, FL—At the Third Annual Conference of the Association for Value-Based Cancer Care, James Lang, PharmD, Vice President of Pharmacy Services at BlueCross BlueShield of Michigan (BCBSM), shared his company’s approach to new managed market challenges.
Read Article

Hollywood, FL—At the Third Annual Conference of the Association for Value-Based Cancer Care, Sandra M. Swain, MD, FACP, President of the American Society of Clinical Oncology (ASCO) and Medical Director of Washington Cancer Institute in Washington, DC, described efforts by ASCO to enhance the quality and cost-effectiveness of the cancer care its members provide.
Read Article

Page 3 of 5